| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |